Abstract:Fabrizio Martora, Teresa Battista, &ast Luca Potestio, &ast Antonio Portarapillo, Nello Tommasino, Matteo Megna Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy &astThese authors contributed equally to this work Correspondence: Fabrizio Martora, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, 80131, Italy, Tel +39 081 7462457, Fax +39 081 7462442, Email Managing HS has long posed a significant challenge for dermatologists. Adalimumab stands as the sole biologic drug sanctioned for HS, receiving approval in 2015 as an anti-tumor necrosis factor (TNF)-α drug. Real-life evidence over the years has debated its efficacy, suggesting a success rate hovering around 70%. However, the variability in existing treatments and the chronic-recurrent nature of the condition make its treatment and management exceedingly challenging. Hence, identifying new therapeutic targets for HS in the future becomes imperative. Recently, on October 31, 2023, the FDA approved secukinumab for moderate-severe HS, marking a significant development. There has been substantial discourse on the potential of anti-interleukin-23 drugs as new therapeutic avenues for treating HS in recent years. Here, we report a case of 17-year-old man successfully treated with Guselkumab. The results were confirmed at week 52. Keywords: hidradenitis suppurativa, anti-IL23, guselkumab, adalimumab, secukinumab Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and disabling skin condition that affects hair follicles. It is characterized by painful lesions affecting areas of the body where apocrine glands are present. 1,2 While the precise underlying pathogenic mechanism of HS remains uncertain, initial follicular hyperkeratosis within the pilosebaceous-apocrine unit is considered the primum movens. Recent studies have provided new insights into the role of pro-inflammatory cytokines in HS pathogenesis, helping to address some existing gaps in our understanding of the development of this condition. 3,4 To date, the first FDA-approved biologic drug for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α approved in 2015. Several real-life studies have highlighted a mean clinical success rate of approximately 70%. 5,6 However, primary or secondary lack of efficacy may occur. 7–10 Secukinumab, an anti-interleukin 17A drug approved for moderate to severe psoriasis and psoriatic arthritis (PsA), has shown promising results in clinical trials by improving signs and symptoms of HS with a good safety profile, maintaining a positive response for up to 52 weeks. 11 Even a few real-life data already align with these studies. 11 Recently, the European Commission (EC) approved secukinumab for use in adults with active moderate to severe HS, 12 while FDA approval was granted just a few months ago (October 31, 2023). Managing HS still remains challenging due to the variable outcomes of available treatments, and its chronic-recurrent nature; there is a huge need of new therapeutic targets for HS in order to take control of the disease in long-term. In this context, significant attention has been directed toward understanding the role of anti-IL-23 drugs in treating HS, thanks to the real-life studies and experiences recently published in literatures. Presently, there are three Phase 2 studies investigating these drugs alongside several case studies and case series, showcasing highly variable outcomes 12 Indeed, different drugs with diverse mechanism of action are being tested for HS (eg spesolimab, porvocitinib and bimekizumab). 13–15 Here, we report a case of 17-year-old man affected by HS since 3 years presenting nodules and fistulous routes in the axillary cavity, inguinal region, and on the buttocks (Hurley stage II, IHS4 16) (Figure 1A–C). His medical history was unremarkable except heart failure (NYHA1) related to surgery performed in childhood for a congenital atrial shunt. His family history was negative for inflammatory disease except for Crohn's disease (father). The patient had already been on several courses of antibiotics with rifampicin (600 mg) and clindamycin (600 mg) for up to 8 weeks or tetracyclines up to 8 weeks without receiving substantial benefit. Hence, we decided to start Guselkumab following the dosing for adult psoriasis, 100 mg at week 0 and week 4 followed by a maintenance dose every 8 weeks 16–18 avoiding adalimumab and secukinumab due to possible contraindications (heart failure and Crohn's disease familiarity, respectively). At week 16 HiSCR (Hidradenitis Suppurativa Clinical Response) was achieved (IHS4 6), lesions were reduced in bot -Abstract Truncated-

Clinical and Epidemiological Characteristics of Hidradenitis Suppurativa Patients with Paradoxical Psoriasiform Reactions following Treatment with Adalimumab

Adalimumab-induced paradoxical psoriasis treated with biologics targeting the IL-17/IL-23 axis in patients with hidradenitis suppurativa

Assessing the Role of Adalimumab in Treating Hidradenitis Suppurativa: Findings from a Retrospective Study at a Reference Center

Adalimumab Treatment Effects on Inflammation and Adipose Tissue Mitochondrial Respiration in Hidradenitis Suppurativa

Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study

Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa

Hidradenitis Suppurativa from a Multi-Omic Scope

P230 Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry

Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape

New-Onset Hidradenitis Suppurativa in Psoriasis Patients: A Multi-Center, Retrospective Cohort Study

Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in Macrophages

Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa

Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient‐reported ethnicity

Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy

Real‐world adalimumab survival and discontinuation factors in hidradenitis suppurativa

Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report

Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa

Comparative efficacy and therapeutic positioning of biologics in hidradenitis suppurativa: A systematic review with network meta-analysis of randomised trials

Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments